Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Karius Inc. is currently managing its patent interests within the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action that requires attention. This specific matter is assigned to 1 distinct examiner, BAUSCH, SARAE L, who handles the entirety of the active workload. The prosecution is concentrated within 1 distinct art unit, showing the administrative path for the current filings.
BAUSCH, SARAE L is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This level of concentration means that the company's legal strategy is tied to the specific examination tendencies of a single individual. There are no other examiners or art units currently involved in the company's pending matters. The focus within the Biotechnology & Pharmaceuticals sector suggests the technical scope for the current filings.
For a practitioner, this data highlights a prosecution environment with a single point of contact. The outcome of the active office action will define the immediate success of the portfolio. Because only 1 distinct examiner and 1 distinct art unit are involved, there is no need to navigate varying procedural styles or conflicting interpretations of patent law. The focus remains entirely on the interaction with BAUSCH, SARAE L.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.6% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18349071 | RAPID, NON-INVASIVE DETECTION AND SERIAL MONITORING OF INFECTIONS IN SUBJECTS USING MICROBIAL CELL-FREE DNA SEQUENCING | BAUSCH, SARAE L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18349071 | RAPID, NON-INVASIVE DETECTION AND SERIAL MONITORING OF INFECTIONS IN SUBJECTS USING MICROBIAL CELL-FREE DNA SEQUENCING | BAUSCH, SARAE L | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18349071 | RAPID, NON-INVASIVE DETECTION AND SERIAL MONITORING OF INFECTIONS IN SUBJECTS USING MICROBIAL CELL-FREE DNA SEQUENCING | BAUSCH, SARAE L | 1699 | §101§102§103 | Non-Final OA | — | Pending | Jul 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKarius Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sarae L Bausch has the most, with 1 of Karius Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.